136 related articles for article (PubMed ID: 24113653)
1. Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400.
Cameron A; Giacomozzi B; Joyce J; Gray A; Graham D; Ousson S; Neny M; Beher D; Carlson G; O'Moore J; Shearman M; Hering H
FEBS Lett; 2013 Nov; 587(22):3722-8. PubMed ID: 24113653
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
[TBL] [Abstract][Full Text] [Related]
3. Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody.
Yuzwa SA; Yadav AK; Skorobogatko Y; Clark T; Vosseller K; Vocadlo DJ
Amino Acids; 2011 Mar; 40(3):857-68. PubMed ID: 20706749
[TBL] [Abstract][Full Text] [Related]
4. Production of O-GlcNAc Modified Recombinant Tau in E. coli and Detection of Ser400 O-GlcNAc Tau In Vivo.
Yuzwa SA; Vocadlo DJ
Methods Mol Biol; 2017; 1523():237-248. PubMed ID: 27975253
[TBL] [Abstract][Full Text] [Related]
5. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
6. O-GlcNAcylation modulates the self-aggregation ability of the fourth microtubule-binding repeat of tau.
Yu CH; Si T; Wu WH; Hu J; Du JT; Zhao YF; Li YM
Biochem Biophys Res Commun; 2008 Oct; 375(1):59-62. PubMed ID: 18671940
[TBL] [Abstract][Full Text] [Related]
7. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
8. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
[TBL] [Abstract][Full Text] [Related]
10. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.
Gong CX; Liu F; Iqbal K
Alzheimers Dement; 2016 Oct; 12(10):1078-1089. PubMed ID: 27126545
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a site-specific antibody for SIRT1 O-GlcNAcylated at serine 549.
Shan H; Sun J; Shi M; Liu X; Shi Z; Yu W; Gu Y
Glycobiology; 2018 Jul; 28(7):482-487. PubMed ID: 29688431
[TBL] [Abstract][Full Text] [Related]
13. MK-8719, a Novel and Selective
Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
[TBL] [Abstract][Full Text] [Related]
14. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
[TBL] [Abstract][Full Text] [Related]
16. IP-LC-MSMS Enables Identification of Three Tau
Bijttebier S; Rodrigues Martins D; Mertens L; Grauwen K; Bruinzeel W; Willems R; Bartolomé-Nebreda JM; Theunis C; Bretteville A; Ebneth A; Dillen L
J Proteome Res; 2023 Apr; 22(4):1309-1321. PubMed ID: 36888912
[No Abstract] [Full Text] [Related]
17. Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes.
Kang MJ; Kim C; Jeong H; Cho BK; Ryou AL; Hwang D; Mook-Jung I; Yi EC
Exp Mol Med; 2013 Jun; 45(6):e29. PubMed ID: 23807304
[TBL] [Abstract][Full Text] [Related]
18. Semi-synthesis of a tag-free O-GlcNAcylated tau protein by sequential chemoselective ligation.
Schwagerus S; Reimann O; Despres C; Smet-Nocca C; Hackenberger CP
J Pept Sci; 2016 May; 22(5):327-33. PubMed ID: 27071766
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAc modification and the tauopathies: insights from chemical biology.
Yuzwa SA; Vocadlo DJ
Curr Alzheimer Res; 2009 Oct; 6(5):451-4. PubMed ID: 19874270
[TBL] [Abstract][Full Text] [Related]
20. Does O-GlcNAc play a role in neurodegenerative diseases?
Lefebvre T; Guinez C; Dehennaut V; Beseme-Dekeyser O; Morelle W; Michalski JC
Expert Rev Proteomics; 2005 Apr; 2(2):265-75. PubMed ID: 15892570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
